DEFINE trial - Summary & Results

600 views
424 views

Published on

http://www.theheart.org/web_slides/1158009.do

A randomized study on determining the efficacy and tolerability of CETP Inhibition with anacetrapib (DEFINE) with the help of 1623 patients with CHD or at high risk for CHD.

Published in: Health & Medicine, Technology
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
600
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

DEFINE trial - Summary & Results

  1. 1. DEFINE (Determining the Efficacy andTolerability of CETP Inhibition withAnacetrapib)
  2. 2. DEFINE (Determining the Efficacy and Tolerability ofCETP Inhibition with Anacetrapib)C Cannon (Brigham and Women’s Hospital, Boston, MA)American Heart Association 2010 Scientific Sessions• Background: Anacetrapib is a new cholesteryl ester transfer protein (CETP) inhibitor• Population and treatment: 1623 patients with CHD or at high risk for CHD, baseline LDL-C 50–100 mg/dL while taking a statin and HDL-C < 60 mg/dL Randomized to anacetrapib 100 mg or placebo• Outcome: Primary end point: change in LDL-cholesterol levels at 24 weeks and safety and side-effect profile at 76 weeks Secondary end point: change in HDL-cholesterol level
  3. 3. DEFINE: Results• Anacetrapib significantly decreased LDL-C by 36% and increased HDL-C by 138% when compared with placebo• SBP, electrolytes, aldosterone, mortality and CV events were similar in both groupsChanges in lipid parameters (mg/dL) in the anacetrapib-treated patientsVariable Baseline Week 24 Week 76LDL-C 81.2 44.7 48.9HDL-C 40.5 101.2 102.3Non–HDL-C 109.7 69.7 73.0Apolipoprotein B 88.4 70.1 69.6Apolipoprotein A1 142.5 208.0 203.0Total cholesterol 150.3 170.8 175.2Lipoprotein(a) 26.8 14.8 16.4
  4. 4. DEFINE: Commentary*"I think the very exciting thing is that were entering an era where we havemedications that raise HDL cholesterol." - Dr Christopher Cannon"Weve gone as far with statins as we can go, and HDL cholesterol is a verypromising target." -Dr Steven Nissen"With torcetrapib, we saw the rise in aldosterone levels, which led to thehypertension in susceptible patients. With anacetrapib, there is no rise inaldosterone or blood pressure. There are no adverse effects that we can see at all." - Dr Roger Blumenthal*All comments from DEFINE: Large effects on LDL and HDL cholesterol with CETP inhibitoranacetrapib (http://www.theheart.org/article/1151979.do)
  5. 5. Become a member of http://www.theheart.org Become a fan on Facebook: http://www.facebook.com/theheartorg Follow us on Twitter: http://www.twitter.com/theheartorgtheheart.org is the leading online source of independent cardiology news.We are the top provider of news and opinions for over 100 000 physicians.

×